Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QHRD106 Injection for Acute Ischemic Stroke Phase IIb Trial
CTR20254936Phase 2Active
- Sponsor
- Jiangsu Zhonghong Bioengineering Pharmaceutical Research Institute
- Start
- Jan 2026
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ZHB206 in ischemic stroke, sponsored by Jiangsu Zhonghong Bioengineering Pharmaceutical Research Institute. Started Jan 2026; status: active.
02
Drugs
ZHB206
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20254936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254936.